A Phase II Open Label Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

Inclusion Criteria

- Diagnosis of de novo myelodysplastic syndrome of at least 12 weeks duration.

- Baseline mean hemoglobin < 10.0 g/dL (untransfused) and/or be transfusion dependent
defined by requiring at least 4 units of RBC in the 8 weeks prior to baseline.

- More than 30 days must have elapsed since any previous treatment for MDS, other than
transfusion.

- Women must not be pregnant or lactating

- No use of another experimental study drug within 30 dy\ays of baseline

- Understand and sign written informed consent

- Able to adhere to study visit schedule, understand and comply with other protocol
requirements.